Incretin Science, Receptor Mechanics & Sourcing Purity
A clinical translation of GLP-1 and dual GIP/GLP-1 receptor agonists, hypothalamic neuro-circuitry, gastric motility mechanics, and the regulatory terrain of 503A/503B compounding.
The Neurobiology of Appetite & Satiety
GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) are incretin hormones released by the gut in response to eating. GLP-1 comes from L-cells in the distal ileum and colon; GIP comes from K-cells in the duodenum and upper jejunum. Natural GLP-1 lasts only about two minutes before the enzyme DPP-4 breaks it down, which is why long-acting medicines were developed to carry the signal to the pancreas, liver, gut and brain.
Silencing "Food Noise" in the Hypothalamus
The constant mental loop of cravings is not a character defect. GLP-1 receptor agonists act on appetite centers in the hypothalamus and brainstem, and functional neuroimaging (fMRI) studies show a quieter response in the brain's reward regions when people see food cues. That is a measurable change in how food signals land, not a matter of discipline.
Pancreatic Beta-Cell Sensitivity & Glucagon
Incretin agonists enhance glucose-dependent insulin secretion while suppressing inappropriately elevated postprandial glucagon. By lowering glucagon, which reduces glucose output from the liver, and by supporting weight loss, these medicines improve blood sugar control and insulin sensitivity over time.
Slowed Digestion & The Vagus Nerve
The main way these medicines reduce weight is by lowering appetite in the brain. They also slow stomach emptying, an effect that is strongest in the early weeks and fades with continued weekly dosing. This mirrors the Ileal Brake, the body's own feedback loop in which nutrients reaching the lower small intestine release GLP-1 and PYY to slow the upper gut. While chyme stays in the stomach longer, stretch receptors signal fullness to the brain via the vagus nerve.
| Administration Route | Absorption Mechanism | Bioavailability | Clinical Implications |
|---|---|---|---|
| Subcutaneous Injection | Absorbed from the tissue under the skin into the bloodstream | High (about 80% for tirzepatide, 89% for semaglutide) | Half-life of about 5 to 7 days allows once-weekly dosing; bypasses digestion. |
| Oral Semaglutide (Rybelsus; Wegovy tablet, approved Dec 2025) | Peptide protected by an absorption enhancer (SNAC) | Low (about 1 to 2%) | Once daily on an empty stomach with up to 4 oz of water; wait at least 30 minutes before food, drink or other pills. |
| Oral Orforglipron (Foundayo, approved Apr 2026) | Small-molecule (non-peptide) GLP-1 receptor agonist | Absorbed as an ordinary pill | No food or water timing rules. |
503A vs. 503B Compounding Standards & Molecule Purity
Sections 503A and 503B of the Food, Drug, and Cosmetic Act permit compounding under defined conditions, and allow close copies of an approved drug mainly while that drug is on FDA's shortage list. FDA declared the tirzepatide shortage resolved on October 2, 2024 (reissued December 19, 2024), with the grace period ending February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities. FDA declared the semaglutide shortage resolved on February 21, 2025, with grace periods ending April 22, 2025 (503A) and May 22, 2025 (503B). On May 1, 2026 FDA further proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List; the public comment period closed July 30, 2026, and FDA's final decision was still pending as of September 22, 2026. Re-check before relying on it. Facility registration is therefore no longer a sufficient proxy for either legality or quality, and navigating compounding requires rigorous scrutiny of molecule integrity, facility registration, and current regulatory status. Compounded drugs, including those from 503B facilities, are not FDA-approved.
Base Form vs. Salt Derivatives
Compounded medications must utilize the active pharmaceutical ingredient (API) in its base peptide form (e.g., Semaglutide Base). The FDA has explicitly warned against salt formulations (Semaglutide Sodium, Semaglutide Acetate), which have not been clinically established for safety or therapeutic equivalence.
Requirement: Always request verification that your medication is formulated with pure base peptide.
503A vs. 503B Outsourcing Facilities
503A Pharmacies: State-board licensed facilities filling patient-specific prescriptions. Quality standards follow USP <797> sterile compounding.
503B Outsourcing Facilities: FDA-registered facilities that must follow Current Good Manufacturing Practice (CGMP) requirements and are inspected by FDA. Their products are still not FDA-approved: FDA does not review them for safety or effectiveness before they are sold.
Winning Prior Authorizations & Overcoming Step Therapy
Insurance companies utilize automated denial algorithms and "Step Therapy" mandates (requiring patients to fail older, less effective drugs first) designed to create patient attrition. Bypassing these barriers requires documented clinical necessity.
Initial Approval Packet
Documenting baseline BMI ≥ 30 (or ≥ 27 with comorbidities: hypertension, dyslipidemia, prediabetes) and formal failure of comprehensive lifestyle interventions.
Bypassing Step Therapy
Physician documentation of contraindications to older agents (e.g. phentermine tachycardia risk, topiramate cognitive fog, or bupropion seizure risk).
Continuation of Care
Crucial for renewals: many plans set their own renewal rules, such as proof of weight lost since starting, and a normal BMI on treatment can trigger a denial. Ask your plan for its written renewal criteria, and have the re-authorization submitted as "Continuation of Successful Care for Chronic Disease Management."